ARTICLE | Clinical News
RP5063: Completed Phase II enrollment
January 21, 2013 8:00 AM UTC
Reviva completed enrollment of 234 schizophrenia patients in the double-blind, placebo-controlled, international Phase II REFRESH trial comparing 15, 30 or 50 mg daily RP5063 vs. 15 mg daily aripipraz...